Gareth J. Dunseath

Dr. Gareth J. Dunseath

orcid

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2007 in Diabetes Care
Verified
Journal Article
Open access
PDF file
LMLouis Monnier
Louis Monnier
CCClaude Colette
Claude Colette
GDGareth J. Dunseath
Gareth J. Dunseath
DODavid R. Owens
David R. Owens
OBJECTIVE— The aim of the study was to determine whether the loss of fasting and postprandial glycemic control occurs in parallel or sequentially in the evolution of type 2 diabetes.

9 August 2017 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
MAMohammad Alhadj Ali
Mohammad Alhadj Ali
YLYuk-Fun Liu
Yuk-Fun Liu
SASefina Arif
Sefina Arif
DTDanijela Tatovic
Danijela Tatovic
HSHina Shariff
Hina Shariff
CDColin M. Dayan
Colin M. Dayan
Immunotherapy using short immunogenic peptides of disease-related autoantigens restores immune tolerance in preclinical disease models. We studied safety and mechanistic effects of injecting human leukocyte antigen–DR4(DRB1*0401)–restricted immunodominant proinsulin peptide intradermally every 2 or 4 weeks for 6 months in newly diagnosed type 1 diabetes patients. Treatment was well tolerated with no systemic or local hypersensitivity. Placebo subjects showed a significant decline in stimulated C-peptide (measuring insulin reserve) at 3, 6, 9, and 12 months versus baseline, whereas no significant change was seen in the 4-weekly peptide group at these time points or the 2-weekly group at 3, 6, and 9 months. The placebo group’s daily insulin use increased by 50% over 12 months but remained unchanged in the intervention groups. C-peptide retention in treated subjects was associated with proinsulin-stimulated interleukin-10 production, increased FoxP3 expression by regulatory T cells, low baseline levels of activated β cell–specific CD8 T cells, and favorable β cell stress markers (proinsulin/C-peptide ratio). Thus, proinsulin peptide immunotherapy is safe, does not accelerate decline in β cell function, and is associated with antigen-specific and nonspecific immune modulation.

1 February 2010 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Open access
PDF file
NANeera Agarwal
Neera Agarwal
SRSam P. L. Rice
Sam P. L. Rice
HBHemanth Bolusani
Hemanth Bolusani
SLStephen D. Luzio
Stephen D. Luzio
GDGareth J. Dunseath
Gareth J. Dunseath
DRD. Aled Rees
D. Aled Rees
Context: Patients with polycystic ovary syndrome (PCOS) have an increased prevalence of insulin resistance and display subclinical evidence of early cardiovascular disease. Metformin improves insulin sensitivity and circulating markers of cardiovascular risk in patients with PCOS, but it is unclear whether this translates into improvements in vascular function. Objective: Our objective was to evaluate the effects of metformin on arterial stiffness and endothelial function in women with PCOS. Design and Intervention: Thirty women with PCOS were assigned to consecutive 12-wk treatment periods of metformin or placebo in a randomized, double-blind, crossover design separated by an 8-wk washout. Main Outcome Measures: The primary outcome measures were assessments of arterial stiffness [augmentation index (AIx), central blood pressure, and brachial and aortic pulse wave velocity (PWV)] and endothelial function. Anthropometry, testosterone, and metabolic biochemistry (lipids, homeostasis model of assessment for insulin resistance, high-sensitivity C-reactive protein, adiponectin, and plasminogen activator inhibitor-1) were also assessed. Results: Metformin improved AIx [−6.1%; 95% confidence interval (CI) for the difference −8.5 to −3.5%; P < 0.001], aortic PWV (−0.76 m/sec; 95% CI for the difference −1.12 to −0.4 m/sec; P < 0.001), brachial PWV (−0.73 m/sec; 95% CI for the difference −1.09 to −0.38; P < 0.001), central blood pressure (P < 0.001), and endothelium-dependent (AIx after albuterol; P = 0.003) and endothelium-independent (AIx after nitroglycerin; P < 0.001) vascular responses. Metformin also reduced weight (P < 0.001), waist circumference (P < 0.001), and triglycerides (P = 0.004) and increased adiponectin (P = 0.001) but did not affect testosterone or other metabolic measures. Conclusions: Short-term metformin therapy improves arterial stiffness and endothelial function in young women with PCOS.

1 January 2007 in COPD: Journal of Chronic Obstructive Pulmonary Disease
Verified
Journal Article
Closed access
CBC. E. Bolton
C. E. Bolton
MEM. Evans
M. Evans
AIA. A. Ionescu
A. A. Ionescu
SES. M. Edwards
S. M. Edwards
RMR. H.K. Morris
R. H.K. Morris
DSD. J. Shale
D. J. Shale
Chronic obstructive pulmonary disease (COPD) is associated with a continuous systemic inflammatory response. Furthermore, COPD is associated with an excess risk for cardiovascular disease and type II diabetes. Systemic inflammation in other populations is a factor in atherogenesis and has been associated with insulin resistance. We assessed the association between systemic inflammation and insulin resistance in non-hypoxaemic patients with COPD. Fasting plasma glucose, insulin and inflammatory mediators were measured in 56 patients and 29 healthy subjects. Body mass index (BMI) and height squared fat- and fat-free-mass index were similar between subject groups. Using homeostatic modelling techniques, mean (SD) insulin resistance was greater in the patients, 1.68 (2.58) and 1.13 (2.02) in healthy subjects, p = 0.032. Fasting plasma insulin was increased in patients while glucose was similar to that in healthy subjects. Patients had increased circulating inflammatory mediators. Insulin resistance was related to interleukin-6 (IL-6), r = 0.276, p = 0.039, and tumour necrosis factor α soluble receptor I, r = 0.351, p = 0.008. Both IL-6 and BMI were predictive variables of insulin resistance r2 = 0.288, p < 0.05. We demonstrated greater insulin resistance in non-hypoxaemic patients with COPD compared with healthy subjects, which was related to systemic inflammation. This relationship may indicate a contributory factor in the excess risk of cardiovascular disease and type II diabetes in COPD.

20 March 2014 in Scandinavian Journal of Medicine & Science in Sports
Verified
Journal Article
Closed access
PDF file
DTD. Turner
D. Turner
SLS. Luzio
S. Luzio
BGBenjamin Gray
Benjamin Gray
GDGareth J. Dunseath
Gareth J. Dunseath
ERE. D. Rees
E. D. Rees
RBRichard M. Bracken
Richard M. Bracken

1 March 2005 in Diabetes Care
Verified
Journal Article
Open access
PDF file
RPRajesh Peter
Rajesh Peter
SLStephen D. Luzio
Stephen D. Luzio
GDGareth J. Dunseath
Gareth J. Dunseath
AMAndy Miles
Andy Miles
BHBarry Hare
Barry Hare
DODavid R. Owens
David R. Owens
OBJECTIVE—To study the effects of exercise on the absorption of the basal long-acting insulin analog insulin glargine (Lantus), administered subcutaneously in individuals with type 1 diabetes. RESEARCH DESIGN AND METHODS—A total of 13 patients (12 men, 1 woman) with type 1 diabetes on a basal-bolus insulin regimen were studied. 125I-labeled insulin glargine at the usual basal insulin dose was injected subcutaneously into the thigh on the evening (2100) before the study day on two occasions 1 week apart. Patients were randomly assigned to 30 min intense exercise (65% peak oxygen uptake [Vo2peak]) on one of these visits. The decay of radioactive insulin glargine was compared on the two occasions using a thallium-activated Nal gamma counter. Blood samples were collected at regular intervals on the study days to assess plasma glucose and insulin profiles. RESULTS—No significant difference was found in the 125I-labeled insulin glargine decay rate on the two occasions (exercise vs. no exercise; repeated-measures ANOVA, P = 0.548). As expected, a significant fall in plasma glucose was observed over the exercise period (area under curve above fasting [ΔAUC] glucose: −0.39 ± 0.11 vs. −1.30 ± 0.16 mmol · l−1 · h−1; nonexercise vs. exercise; P = 0.001), but insulin levels did not differ significantly on the two occasions (ΔAUC insulin: −2.1 ± 3.9 vs. 1.5 ± 6.2 pmol · l−1 · h−1; nonexercise versus exercise; P = 0.507). CONCLUSIONS—An intense 30-min period of exercise does not increase the absorption rate of the subcutaneously injected basal long-acting insulin analog insulin glargine in patients with type 1 diabetes.